Anything is
Druggable

with Quantum Accuracy

They support us:

Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases.

No target
is undruggable

Our proprietary technologies, the fruit of over 30 years of research, make it possible to develop novel drug candidates and innovative modes of action against targets previously considered too complex.

Atlas

Our ultra-high resolution drug design platform, Atlas, enables drug hunters to discover, optimize & validate drug candidates and carry out complex computations at scale, on any hardware, whether on-premises or on the cloud.

polarizable force fields

State of the art last generation models, such as AMOEBA, reaching chemical accuracy included in ATLAS.

Sirius

Cutting-edge AI & Machine Learning solutions for efficient generative and predictive modeling of small molecules.

TINKER-HP

Fastest and most scalable Molecular Dynamics Software for polarizable force fields, accelerating AMOEBA calculations by a factor >100,000x.

Hyperion

Proprietary Quantum Simulation Platform. Development of next generation algorithms for quantum chemistry & drug discovery.

Gaia

Gaia is our 200 GPU supercomputer, created in collaboration with global leader Nvidia.

By marrying the best hardware technology to cutting-edge software, Atlas is able to carry out computations at scale with quantum accuracy to discover new drugs.

1000+

nanoseconds

1000ns of MD simulation per day with polarizable force fields

Over 50 PetaFLOPS AI dedicated to advanced chemical space exploration

30+

qubits

Hybrid HPC-QC ready for computations over 30 qubits

Behind every target deemed too complex is a real patient with unmet needs.

We are developing novel drugs to cure life-threatening diseases, with a primary focus on oncology, inflammation and pandemic response.

We have multiple fully owned & partnered programs in discovery and are pursuing a broad pipeline of additional targets.

We actively shift the paradigm in drug discovery from drug hunting to drug farming.

A p

Robert Marino, PhD
CEO Qubit Pharmaceuticals

Project pipeline

TARGET / Pathway

therapeutics areas

Target/ MOA characterisation

Hit to lead

Lead to pre-candidate

partner

KAT6A

Oncology

IL4R 

Inflammation

mRas

Oncology

TREX1

Sting Pathway

Undisclosed GPCR

Multiple

RNA - RBP Platform

Oncology & Inflammation

Antivirals
Platform

Multiple targets in partnerships

Various

+ 16 additional drug discovery programs under evaluation

Project pipeline

IL4R

Inflammation

Target / MOA
characterisation

Hit to lead

Lead to
pre-candidate

USP7

Oncology

Target / MOA
characterisation

Hit to lead

Lead to
pre-candidate

MRas

Ras driven oncology

Target / MOA
characterisation

Hit to lead

Lead to
pre-candidate

KAT6A

Oncology

Target / MOA
characterisation

Hit to lead

Lead to
pre-candidate

Undisclosed Metalloenzyme

Oncology

Target / MOA
characterisation

Hit to lead

Lead to
pre-candidate

Undisclosed GPCR

Oncology & Inflammation

Target / MOA
characterisation

Hit to lead

Lead to
pre-candidate

+16 additional discovery programs

Various

Various

Target / MOA
characterisation

Hit to lead

Lead to
pre-candidate

01

supercomputer

40+

drug discovery programs brought to preclinicals and clinical stages by team members during their careers.

30+

PhDs

500+

publications

$25m+

raised

Meet
our
founders

Expert in High Performance Computing, numerical methods and sampling. Lead developer Tinker-HP. Atos Fourier Prize Laureate.

Expert in drug discovery. 8 patents. 1 program at clinical stage.

Expert in quantum chemistry and High Performance Computional. Atos Fourier Prize and ERC Synergy Laureate. Scientific leader Tinker-HP. Fellow of the Royal Society of Chemistry (London).

Expert in structural biology and biomolecular simulation. Fellow of AAAS and past Gordon conference chairperson. Lead developer Tinker and AMOEBA.

Professor of Biomedical Engineering. Expert in multi-scale modelling of proteins and nucleic acids. Lead developer Amoeba.

One team, one mission, infinite ambition

Based in Paris and Boston, our team of over 40 people is made up of over 12 different nationalities. We are a diverse mix of various expertise, backgrounds and perspectives. Our mission? To have a real positive impact on drug design and discovery through computational technology and create treatments that transform lives.

JOIN THE TEAM

Developing better drugs, together

Drug discovery is very much a team effort. We are always looking to explore ways to develop novel treatments to cure major diseases.

We’re looking for partners to co-develop our drug discovery programs. We’re also keen to evaluate the possibility to jointly accelerate existing drug discovery programs or unlock complex targets with the support of Atlas and our drug discovery team.

We’re interested in expanding our portfolio in inflammation and oncology. We’re seeking for novel targets with ideally a crystal structure available, PDX and/or patient lines available and a lab stage assay. Prior demonstration of druggability is not mandatory.

Interested in partnering with us?

Latest news

June 6, 2024

Press Release

Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum

Read the article

January 30, 2024

Press Release

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux Join Forces to Advance the Development of Novel Cancer Therapies

Read the article

December 13, 2023

Press Release

Qubit Pharmaceuticals strengthens its commitment to DistriQ - Quantum Innovation Zone by partnering with the PINQ² platform in order to accelerate pharmaceutical research through quantum computing

Read the article

December 6, 2023

Press Release

Qubit Pharmaceuticals and Sorbonne University achieve a major scientific breakthrough by simulating quantum calculations at more than 40 qubits on conventional computers

Read the article

November 16, 2023

Linkedin

Qubit Pharmaceuticals Invests €4.5M in Innovative RNA Therapeutics Platform!

Read the article

November 9, 2023

Linkedin

Advancing Quantum Chemistry with Quantum Computing: A Pioneering Approach to Sparse Quantum State Preparation for Strongly Correlated Systems

Read the article

November 7, 2023

Linkedin

Qubit Pharmaceuticals honored to announce the arrival of renowned Quantum Computing researcher Dr. Alberto Peruzzo as R&D Lead in Quantum Computing

Read the article

September 28, 2023

Linkedin

Revolutionizing Drug Discovery: Quantum Computing Meets Solvent Configuration Prediction

Read the article

September 26, 2023

Linkedin

French start-ups Pasqal and Qubit Pharmaceuticals join with Unitary Fund to win Wellcome Trust's "Quantum for Bio" program

Read the article

June 12, 2023

Linkedin

Qubit Pharmaceuticals joins the Acuité Québec Consortium to innovate in drug design

Read the article

May 22, 2023

Linkedin

"The purpose of Qubit Pharmaceuticals is to treat patients."

Read the article

May 12, 2023

Linkedin

Qubit Pharmaceuticals is joining the partner ecosystem of Eviden , an Atos business!

Read the article

March 31, 2023

Linkedin

Qubit Pharmaceuticals is a laureate of the very first class of the French Tech #Health20!

Read the article

March 14, 2023

Linkedin

Thanks a lot France Digitale and XAnge for identifying us as a future digital champion!

Read the article

January 24, 2023

Linkedin

A big step forward for quantum computer-assisted #drugdiscovery at Qubit Pharmaceuticals!

Read the article

November 30, 2022

Nvidia

Qubit Pharmaceuticals Accelerates Drug Discovery With Hybrid Quantum Computing

Read the article

November 29, 2022

Linkedin

HPC Innovation Excellence Award

Read the article

November 7, 2022

Linkedin

We are part of Fujitsu Accelerator Program for CaaS !

Read the article

March 31, 2023

Linkedin


Qubit Pharmaceuticals is a laureate of the very first class of the French Tech #Health20!

Read the article